Why Choosing A Client-Centric CTDMO Is Critical When Outsourcing Biomanufacturing Projects
![Doctor businessman shaking hands GettyImages-1098284154 Doctor businessman shaking hands GettyImages-1098284154](https://vertassets.blob.core.windows.net/image/aa7bc266/aa7bc266-2953-4491-845c-f95be3b4c9d9/375_250-doctor_businessman_shaking_hands_gettyimages_1098284154.jpg)
Biologic drug development, encompassing monoclonal antibodies and other large molecules produced in mammalian cells, is experiencing significant growth. While certain biologic drugs have established manufacturing processes, biomanufacturers still face a number of challenges and bottlenecks with bioprocess optimization, capacity limitations, supply chain hurdles, and regulatory requirements.
A promising solution for companies that lack the technical expertise and comprehensive in-house capacity to address these issues is outsourcing various drug development phases to an end-to-end specialized Contract Testing, Development, and Manufacturing Organization (CTDMO). A CTDMO can serve as either a service provider or a collaborative partner in strategic thinking. Thus, selecting the right CTDMO partner is crucial for the success of the biomanufacturing project.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.